Yahoo Suche Web Suche

Suchergebnisse

  1. Suchergebnisse:
  1. Spark Therapeutics. Coming Soon: Spark’s Gene Therapy Innovation Center. Located in West Philadelphia in the heart of University City, our 500,000-square-foot, multi-story Gene Therapy Innovation Center will serve as a Roche center of excellence for gene therapy manufacturing globally.

  2. www.roche.com › innovation › structureRoche | Spark

    Spark Therapeutics was founded in 2013 and became a Member of the Roche Group in 2019. The organisation is a fully integrated, commercial company committed to discovering, developing and delivering gene therapies for genetic diseases, including inherited retinal disorders, haemophilia, lysosomal storage disorders and neurodegenerative diseases.

  3. Products and pipeline. The company has 3 gene therapy product candidates in clinical development: (i) SPK-8011, a candidate in the SPK-FVIII program for hemophilia A; (ii) SPK-8016, a product candidate for the hemophilia A inhibitor market; and (iii) SPK-7001, targeting choroideremia, or CHM.

  4. At Spark Therapeutics, we’re working to unlock the power of gene therapy to accelerate healthcare transformation. Founded in March 2013 as a result of the technology and know-how accumulated over two decades at Children’s Hospital of Philadelphia (CHOP), our investigational therapies have the potential to provide long-lasting effects ...

  5. Spark Therapeutics, Inc. | LinkedIn. Biotechnology Research. Philadelphia, PA 87,207 followers. Our mission is to unlock the power of gene therapy to accelerate healthcare transformation. View...

  6. 23. Feb. 2022 · Spark Therapeutics is a fully integrated, commercial company committed to discovering, developing and delivering gene therapies. Founded in 2013, Spark Therapeutics is the first company in the U.S. to receive FDA approval of a gene therapy for a genetic disease.

  7. 12. Dez. 2022 · Spark Therapeutics, Inc. Multi-year data, with up to five years of follow up, show sustained expression of FVIII in more than 90% of participants, in addition to improved annual bleeding and...